Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sarepta Therapeutics, Inc.
Age
Any age
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Is willing to provide informed assent or consent (if applicable) and has a parent(s) or legal guardian(s) or is a participant ≥18 years of age who is (are) willing to provide informed consent for the participant to participate in the study and comply with study data collection procedures.
Has an established clinical diagnosis of DMD, as documented prior to screening by a genetic report.
Receiving, or initiating treatment with, eteplirsen, golodirsen, or casimersen at the time of observational study enrollment. Note: Participants with a prescription for eteplirsen, golodirsen, or casimersen at enrollment must initiate the exon-skipping therapy within 6 months of the date of enrollment or will no longer be eligible for this study. Note: Enrollment of eteplirsen participants has been completed, no additional participants will be enrolled.
You may not be if
Is currently participating in any DMD interventional study at the time of this study enrollment.
Has declined to provide consent for collection of their genetic data.
Has a medical condition or confounding circumstances that, in the opinion of the Investigator, might compromise:
1. The participant's ability to comply with the protocol-required procedures
2. The participant's wellbeing or safety, and/or
3. The clinical interpretability of the data collected from the participant.
Clareo Health | A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice
